Related content

Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?

By Pitoia Fabián   Degrossi Osvaldo   Niepomniszcze Hugo  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 31, Iss. 6, 2004-06 ,pp. : 924-924

Springer Publishing Company

Access to resources Recommend Favorite

Thyroid Arterial Embolization to Treat Graves' Disease

By Zhao W.   Gao B. -L.   Yang H. -Y.   Li H.   Song D. -P.   Xiang S. -T.   Shen J.  

Acta Radiologica, Vol. 48, Iss. 2, 2007-01 ,pp. : 186-192

Blackwell Publishing

Access to resources Recommend Favorite

Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer

By An Young-Sil   Yoon Joon-Kee   Lee Su   Song Hee-Sung   Yoon Seok-Ho   Jo Kyung-Sook  

Annals of Nuclear Medicine, Vol. 27, Iss. 4, 2013-05 ,pp. : 386-391

Springer Publishing Company

Access to resources Recommend Favorite

Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves’ disease

By Dunkelmann Simone   Kuenstner Hubertus   Nabavi Elham   Rohde Bettina   Groth Peter   Schuemichen Carl  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Iss. 2, 2007-02 ,pp. : 228-236

Springer Publishing Company

Access to resources Recommend Favorite

Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?

By Lucignani Giovanni  

European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Iss. 9, 2007-09 ,pp. : 1504-1509

Springer Publishing Company

Access to resources Recommend Favorite